"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • For Professionals
  • FDA Approvals
  • Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

16 Jul 2021 7:00 AM | Katy Monaco (Administrator)
Food and Drug Administration approved FoundationOne Liquid CDx as a companion diagnotic for TABRECTA (capmatinib.) FoundationOne Liquide CDx is now approved to identify patients with MED exon 14 (METex14) skipping metastatic non-small cell lung cancer (NSCLC) who may be appropriate for treatment with TABRECTA (capmatinib). Press Release. July 15, 2021. Drug Information.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software